Advanced Disease
Treatment of Advanced Insulinoma with Unresectable or Metastatic Disease
Clinical Scenario
When insulinoma presents as unresectable or metastatic disease, surgical cure is not achievable. Management shifts to a multimodal approach — encompassing supportive, medical, interventional, and surgical elements — aimed at controlling the functional consequences of excess insulin secretion.
Primary Goal
Control of insulinoma-related hypoglycaemia — achieving a sustained state free of hypoglycaemic events.
Treatment Approach (Partial Overview)
Management centres on a structured dietary strategy to prevent prolonged hypoglycaemia, alongside specific acute rescue measures for hypoglycaemic episodes. A recognised first-line pharmacological agent is incorporated, with further options available when initial control proves insufficient. The complete structured regimen — including full sequencing and criteria — is available via the link below.
References
DOI: 10.1111/jne.13318
The management of functioning Pan-NET syndromes in patients with advanced disease, that is, unresectable or metastatic, requires a multimodal approach consisting of supportive, medical, interventional and surgical treatment.
In the control of insulinoma-related hypoglycaemia, fractioned diet including complex carbohydrates with slow absorption is the cornerstone to avoid prolonged fasting.
Simple carbohydrates as well as glucose infusion are required in hypoglycaemic events.
To manage acute episodes of hypoglycaemia, glucagon therapy is now available in different formulations (intramuscular, subcutaneous, intranasal).
First-line medical therapy for advanced insulinoma consists of diazoxide (50–600 mg daily).
In cases of refractory hypoglycaemia, incidental descriptions also support the use of glucocorticoids, verapamil, and diphenylhydantoin.
View source ↗